Emerging Therapies in Non–Clear Cell Renal Cell Carcinoma

EP: 1.CLEAR Trial: Lenvatinib Plus Pembrolizumab in Advanced Renal Cell Carcinoma

EP: 2.Recent Data on Lenvatinib Plus Pembrolizumab in Advanced RCC

EP: 3.Clinical Trial Data Updates in Advanced Renal Cell Carcinoma

EP: 4.Clear Cell RCC: Strategies for Selecting Appropriate Frontline Treatment

EP: 5.Second-Line Treatment Options for Patients With Clear Cell RCC

EP: 6.Strategies for Sequencing Therapies in Renal Cell Carcinoma

EP: 7.Safety Profiles of Treatment Regimens for Clear Cell RCC

EP: 8.Future Outlook of Treatment for Clear Cell RCC

EP: 9.RCC Histologies: Clear Cell vs Non–Clear Cell

EP: 10.Updates from ASCO 2023 for Non–Clear Cell RCC

Now Viewing

EP: 11.Emerging Therapies in Non–Clear Cell Renal Cell Carcinoma

Transcript:

Robert J. Motzer, MD: With regard to non–clear cell RCC [renal cell carcinoma], it’s been difficult to study because of the rarity of these tumors and heterogeneity. But I think this is recognized, and there are efforts under way to identify better treatments for that particular group. One of the particularly interesting compounds is XL092, referred to as zanzalintinib. That is a cabozantinib-like compound that has a shorter half-life than cabozantinib. The hope is that it’s better tolerated than cabozantinib. It’s been in phase 1/2 clinical trials either on its own or in combination with IO [immuno-oncology] therapy. One of the emphases of that particular trial, STELLAR-002 [NCT05176483], is to look at that compound in combination with IO therapies in patients with non–clear cell RCC. So I think that’s an important trial to watch and to keep your eye on in terms of that moving forward.

There is also a large randomized trial, called the SAMETA trial [NCT05043090], that is comparing sunitinib as a standard arm to savolitinib or savolitinib plus durvalumab. One is a MET inhibitor, and the other is a PD-1 inhibitor. So that’s a 3-arm trial that’s kind of also exploring a MET inhibitor or a MET inhibitor plus PD-1 inhibitor. One of the differences in that trial is that it selects only patients who have better-expressing MET. It’s really one of the first or unique trials that’s basing the eligibility on a molecular characterization in RCC. And so that’s a large phase 3 trial that is ongoing that I also think should be on our radar.

Transcript is AI-generated and edited for clarity and readability.